Calima Energy Limited (ASX:CE1) Managing Director, Alan Stein, presents on results from the 3 well drill program at the Montney project, strategy and recent capital raising, at the FNN Investor Event.
Key points: - Founded in 2015 by experienced nuclear medicine executives
- Develops diagnostic and therapeutic radiopharmaceuticals
- Specialises in metastatic prostate cancer, renal cell cancer, brain cancer
- Early revenue generation from prostate cancer imaging product
- Prostate cancer radionuclide therapy is $2b opportunity
- Renal cancer patients are often mis-staged, a niche $250m opportunity
- The treatment of GBM is a $300m market opportunity
For more, watch Managing Director Alan Stein present.
